Antineoplastic activity of artemisinin in adrenocortical carcinoma
- 24 Downloads
Artemisia annua is a medicinal plant that is used in China to treat various diseases for over two millenniums. Preclinical studies revealed that the compound has a cytotoxic activity against various types of cancer cells .
Data on anticancer activity of artemisinin in humans are limited, but case reports and small case series have shown encouraging results in patients affected by metastatic breast cancer, colorectal cancer, and uveal melanoma .
The main mechanism of artemisinin antineoplastic activity is not fully elucidated. This drug and relevant derivatives display a multitarget activity, as frequently observed in most natural products . Indeed, artemisinin compounds could block the activation of intracellular pathways such as Wnt/β-catenin, BCR/ABL, or by inducing cell cycle arrest, alteration of DNA repair mechanisms and inducing death via apoptosis and nonapoptotic pathways.
Concerning the artemisinin safety profile, reported adverse effects, such as renal, hepatic, and...
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This study was supported with the contribution of FIRM Foundation (Cremona, Italy).
Informed consent was obtained from the patient included in the study.
- 11.M. Fassnacht, O.M. Dekkers, T. Else, E. Baudin, A. Berruti, R.R. de Krijger et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 179(4), G1–G46 (2018)CrossRefGoogle Scholar
- 13.P. Sperone, A. Ferrero, F. Daffara, A. Priola, B. Zaggia, M. Volante et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr. Relat. Cancer 17(2), 445–453 (2010)CrossRefGoogle Scholar
- 16.D. Cosentini, S. Grisanti, V.A. Dalla, M. Laganà, C. Fiorentini, P. Perotti et al. Immunotherapy failure in adrenocortical cancer: where next? Endocr. Connect. 7(12), E5–E8 (2018)Google Scholar